3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Sarcoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Gemcitabine
4
pembrolizumab
3
Docetaxel
3
Cryosurgery
3
Biopsy
3
eribulin
2
durvalumab
2
balstilimab
2
atezolizumab
2
aflibercept
2
Zoledronic Acid
2
Trastuzumab
2
Taxes
2
Specimen Handling
2
Radiotherapy
2
Radiosurgery
2
Radiation
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Letrozole
2
Irinotecan
2
Gene Expression Profiling
2
Fulvestrant
2
Cisplatin
2
Blood Specimen Collection
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
trifluridine tipiracil drug combination
1
tremelimumab
1
trastuzumab deruxtecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Interleukin-15
×
Sarcoma
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled